Citadel Advisors
FLGT icon

Citadel Advisors’s Fulgent Genetics FLGT Stock Holding History

Citadel Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162K Buy
+10,200
New +$221K ﹤0.01% 11615
2025
Q3 		– Sell
-24,800
Closed -$493K – 13171
2025
Q2 		$493K Sell
24,800
-14,200
-36% -$277K ﹤0.01% 8669
2025
Q1 		$659K Buy
39,000
+6,600
+20% +$112K ﹤0.01% 7859
2024
Q4 		$598K Buy
32,400
+21,100
+187% +$412K ﹤0.01% 8165
2024
Q3 		$246K Buy
11,300
+3,300
+41% +$73.8K ﹤0.01% 9722
2024
Q2 		$157K Sell
8,000
-20,500
-72% -$428K ﹤0.01% 10276
2024
Q1 		$618K Sell
28,500
-47,400
-62% -$1.18M ﹤0.01% 7925
2023
Q4 		$2.19M Sell
75,900
-24,200
-24% -$648K ﹤0.01% 5198
2023
Q3 		$2.68M Buy
100,100
+34,300
+52% +$1.17M ﹤0.01% 4698
2023
Q2 		$2.44M Sell
65,800
-3,500
-5% -$122K ﹤0.01% 4812
2023
Q1 		$2.16M Buy
69,300
+600
+0.9% +$19.3K ﹤0.01% 5210
2022
Q4 		$2.05M Buy
68,700
+14,200
+26% +$508K ﹤0.01% 5442
2022
Q3 		$2.08M Sell
54,500
-700
-1% -$35.1K ﹤0.01% 5522
2022
Q2 		$3.01M Sell
55,200
-52,700
-49% -$2.9M ﹤0.01% 4750
2022
Q1 		$6.73M Buy
107,900
+50,600
+88% +$3.33M ﹤0.01% 3615
2021
Q4 		$5.76M Sell
57,300
-34,100
-37% -$3M ﹤0.01% 4052
2021
Q3 		$8.22M Sell
91,400
-86,600
-49% -$7.87M ﹤0.01% 3412
2021
Q2 		$16.4M Sell
178,000
-131,200
-42% -$10.5M ﹤0.01% 2337
2021
Q1 		$29.9M Sell
309,200
-129,400
-30% -$13.4M 0.01% 1513
2020
Q4 		$22.9M Buy
438,600
+371,000
+549% +$15.5M 0.01% 1662
2020
Q3 		$2.71M Buy
+67,600
New +$2.12M ﹤0.01% 4162

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's FLGT Position: Q1 2026 in Review

Citadel Advisors reduced its Fulgent Genetics (FLGT) stake by 78% in Q1 2026, selling an estimated $4.13M and leaving 52,948 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #8055.

Citadel Advisors first reported a position in FLGT in Q3 2020 and has held it in 23 quarters since. The position peaked at $23.2M in Q3 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Citadel Advisors held 52,948 shares of Fulgent Genetics worth $842K as of Q1 2026.
  • Citadel Advisors sold 190,176 Fulgent Genetics shares in Q1 2026, an estimated $4.13M.
  • Fulgent Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8055 holding.
  • Citadel Advisors first reported a position in Fulgent Genetics in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Fulgent Genetics position peaked at $23.2M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.